Models
ASTRAZENECA PHARMA IND LTASTRAZENPharmaceuticals & Biotechnology
₹1,317per share · Base Model Note
Revenue growth, the horizon and scenarios are yours to change. Every other input is part of the Trader plan; saving, sharing a saved link and the live-formula workbook are part of the Institutional plan.
Scenario
Value per share, your model₹1,317implied FY26 P/E 19.4× · EV/EBITDA 11.1×
Against CMP ₹6,755.00−80.5%close of 2026-09-10
Growth the CMP implies45.0%revenue, a year for 5 years, on your other inputs
Value after FY3178%share of enterprise value in the terminal
This figure is the arithmetic of your inputs and nothing else. MarketPing publishes no fair value, target or rating; the model is yours.
Where the methods land · ₹ per share · the dashed line is the CMP
DCF, rate ±1 · growth ±1your model across the sensitivity grid
₹1,053₹1,844
52-week rangetraded range, a fact not a value
₹6,801₹9,850
From enterprise to equity · ₹ crore
| PV of FY27–FY31 free cash flow | 615 |
| PV of terminal value | 2,230 |
| Enterprise value | 2,845 |
| less net debt | 448 |
| less non-controlling interest | 0 |
| add non-operating investments | 0 |
| Equity value | 3,293 |
| ÷ 2.50 crore shares | ₹1,317 |
78% of the value sits after FY31. Usual when return on capital sits near the cost of capital; the 5 explicit years carry little of it.
Free cash flow, filed and modelled · ₹ '000 crore
Filed, cash from operations − capexModelled free cash flow to firm
Sensitivity · ₹ per share
Down Across| WACC ↓terminal growth → | 4.0% | 4.5% | 5.0% | 5.5% | 6.0% |
|---|---|---|---|---|---|
| 10.00% | 1,356 | 1,444 | 1,551 | 1,681 | 1,844 |
| 10.50% | 1,262 | 1,336 | 1,423 | 1,528 | 1,656 |
| 11.00% | 1,183 | 1,245 | 1,317 | 1,403 | 1,506 |
| 11.50% | 1,113 | 1,166 | 1,227 | 1,299 | 1,383 |
| 12.00% | 1,053 | 1,099 | 1,151 | 1,211 | 1,281 |
The outlined cell is your model. Green figures sit above the CMP of ₹6,755.00; n/a marks a terminal growth at or above the discount rate. Steps: WACC and terminal growth ±0.5 point, growth ±2, margin ±1.
Distribution of outcomes · 4,000 draws · growth, margin and the discount rate vary together
| 10th · 50th · 90th percentile, ₹ per share | 880 · 1,291 · 1,692 |
| Draws below the CMP | 100% |
| Rank correlation with ebitda margin | +0.90 |
| Rank correlation with discount rate | −0.32 |
| Rank correlation with revenue growth | −0.22 |
Each driver is drawn from a PERT distribution between the lowest and highest value across your scenarios (or ±50% growth, ±20% margin when there is one scenario), with the discount rate ±1.5 points. Seeded, so the same inputs give the same picture.
Projected cash flow to the firm · ₹ crore
History Forward| ₹ crore | FY23 | FY24 | FY25 | FY26 | FY27 | FY28 | FY29 | FY30 | FY31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,003 | 1,296 | 1,716 | 2,276 | 2,958 | 3,846 | 4,999 | 6,499 | 8,449 |
| growth % | 24.5 | 29.2 | 32.5 | 32.6 | 30.0 | 30.0 | 30.0 | 30.0 | 30.0 |
| EBITDA | 125 | 201 | 157 | 257 | 334 | 435 | 565 | 734 | 955 |
| margin % | 12.5 | 15.5 | 9.2 | 11.3 | 11.3 | 11.3 | 11.3 | 11.3 | 11.3 |
| less depreciation | (16) | (15) | (40) | (29) | (38) | (50) | (65) | (84) | (110) |
| EBIT | 109 | 186 | 117 | 228 | 296 | 385 | 500 | 650 | 845 |
| less tax on EBIT | (58) | (76) | (98) | (128) | (166) | (216) | |||
| NOPAT | 170 | 220 | 286 | 372 | 484 | 629 | |||
| add depreciation | 16 | 15 | 40 | 29 | 38 | 50 | 65 | 84 | 110 |
| less capex | (9) | (11) | (2) | (4) | (6) | (21) | (44) | (79) | (132) |
| less working-capital build | — | (137) | (178) | (232) | (301) | (392) | |||
| Free cash flow to firm | 50 | 82 | 64 | — | 115 | 137 | 161 | 187 | 215 |
| Discount factor | 0.949 | 0.855 | 0.770 | 0.694 | 0.625 | ||||
| Present value | 110 | 117 | 124 | 130 | 134 |
History columns are the filed years (free cash flow there is cash from operations − capex, as filed); the base year and everything to its right come from the engine. Forward is the explicit horizon of the model itself: 3, 5 or 10 years, then flat.
The three statements, projected · ₹ crore · debt held at 0, dividends at 42.7% of profit
| ₹ crore | FY26 | FY27 | FY28 | FY29 | FY30 | FY31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| EBIT | 228 | 296 | 385 | 500 | 650 | 845 |
| Interest at 8% on debt | 0 | 0 | 0 | 0 | 0 | |
| Profit before tax | 296 | 385 | 500 | 650 | 845 | |
| Profit after tax | 188 | 220 | 286 | 372 | 484 | 629 |
| Dividends | (80) | (94) | (122) | (159) | (206) | (268) |
| Balance sheet, year end | ||||||
| Cash | 448 | 469 | 484 | 486 | 467 | 413 |
| Working capital | 458 | 595 | 774 | 1,006 | 1,307 | 1,699 |
| Net block and other assets | 1,083 | 1,051 | 1,021 | 1,000 | 995 | 1,017 |
| Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity | 873 | 999 | 1,163 | 1,376 | 1,653 | 2,013 |
| Balance check | 0 | (0) | (0) | 0 | 0 | 0 |
| Cash flow | ||||||
| From operations | 121 | 158 | 205 | 267 | 347 | |
| Investing (capex) | (6) | (21) | (44) | (79) | (132) | |
| Financing (dividends) | (94) | (122) | (159) | (206) | (268) | |
| Net change in cash | 21 | 15 | 2 | (19) | (54) | |
| Free cash flow to equity | 115 | 137 | 161 | 187 | 215 | |
Other liabilities are held at their FY26 level, so the check tests only what the model moves: cash, working capital, net block and other assets, debt and equity. A non-zero check would mean the three statements no longer tie.
Scenarios side by side · ₹ per share
| Scenario | Template | Growth | Margin | Rate | Terminal | ₹ / share | vs CMP |
|---|---|---|---|---|---|---|---|
| Base · editing | DCF | 30% | 11.3% | 11.00% | 5% | ₹1,317 | (80.5)% |
A scenario is a full set of inputs under a name. Keep Base as the filed history carried forward; add Bull and Bear by saving the current inputs under those names and moving the two or three assumptions you actually hold a view on. The distribution above draws each driver between the lowest and highest value across your scenarios, so three scenarios give it a real range; with one scenario it falls back to fixed bands.